<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer Europe</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Non-profit NGO</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Senningerberg, Luxembourg</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Non-Profit Organization (NGO)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.alzheimer-europe.org/" target="_blank">https://www.alzheimer-europe.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Dementia Research, Policy Advocacy, Human Rights, Prevention, Caregiver Support</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1990</td>
</tr>
<tr>
<td class="label">Member Organizations</td>
<td>41 national Alzheimer's associations from 36 European countries</td>
</tr>
<tr>
<td class="label">Executive Director</td>
<td>Jean Georges</td>
</tr>
</table>
Alzheimer Europe is a non-profit non-governmental organization (NGO) that serves as the umbrella organization for 41 national Alzheimer's associations across 36 European countries[@alzheimer]. Founded in 1990, the organization is dedicated to improving the quality of life for people with dementia and their families across Europe through advocacy, research support, public awareness campaigns, and policy coordination.
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer Europe</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Non-profit NGO</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Senningerberg, Luxembourg</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Non-Profit Organization (NGO)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.alzheimer-europe.org/" target="_blank">https://www.alzheimer-europe.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Dementia Research, Policy Advocacy, Human Rights, Prevention, Caregiver Support</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1990</td>
</tr>
<tr>
<td class="label">Member Organizations</td>
<td>41 national Alzheimer's associations from 36 European countries</td>
</tr>
<tr>
<td class="label">Executive Director</td>
<td>Jean Georges</td>
</tr>
</table>
Alzheimer Europe is a non-profit non-governmental organization (NGO) that serves as the umbrella organization for 41 national Alzheimer's associations across 36 European countries[@alzheimer]. Founded in 1990, the organization is dedicated to improving the quality of life for people with dementia and their families across Europe through advocacy, research support, public awareness campaigns, and policy coordination.
The organization maintains its headquarters in Senningerberg, Luxembourg, and operates as a coordinating body for national dementia associations throughout Europe. Alzheimer Europe plays a pivotal role in shaping European dementia policy, fostering cross-border research collaboration, and representing the voices of people affected by dementia at the European Union level.
Alzheimer Europe's mission is to:
Alzheimer Europe is governed by a board of directors composed of representatives from member organizations across Europe:
The organization benefits from two key working groups that provide expert input:
Alzheimer Europe serves as a critical coordination hub for dementia research across Europe. The organization maintains involvement in numerous European Union-funded research projects through the EU Joint Programme — Neurodegenerative Disease Research (JPND) and other collaborative initiatives[@euprojects].
Research Initiatives:
Alzheimer Europe maintains a strong presence in European policy discussions:
Alzheimer Europe organizes the premier annual dementia conference in Europe:
Alzheimer Europe is committed to ensuring dementia is recognized as a public health priority with equity considerations:
Alzheimer Europe coordinates national Alzheimer's associations from the following 36 countries:
| Region | Countries |
|--------|-----------|
| Western Europe | Austria, Belgium, France, Germany, Luxembourg, Netherlands, Switzerland |
| Northern Europe | Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, United Kingdom |
| Southern Europe | Cyprus, Greece, Italy, Malta, Portugal, Spain |
| Central Europe | Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia |
| Eastern Europe | Bulgaria, Moldova, Russia, Turkey, Ukraine |
This extensive network enables Alzheimer Europe to represent the collective interests of millions of people affected by dementia across the continent.
Alzheimer Europe participates in numerous EU-funded research and policy projects:
The organization maintains relationships with:
Alzheimer Europe provides various resources for people affected by dementia and professionals:
Alzheimer Europe has played a critical role in:
Alzheimer Europe was established in 1990 as a response to the growing dementia crisis across Europe. The organization emerged from recognition that dementia—particularly Alzheimer's disease and related conditions—required a coordinated European response that individual national associations could not achieve alone. The founding vision was to create a unified voice for people affected by dementia across the continent, advocate for policy changes at the European level, and foster research collaboration among European nations.
The early years focused primarily on information sharing between member organizations and raising awareness about dementia at the European Parliament and European Commission. Initial activities included organizing biennial conferences, publishing informational materials, and building relationships with European policymakers. These foundational efforts established the organizational structure and network that would later enable more ambitious research coordination and policy advocacy.
Throughout the 1990s and early 2000s, Alzheimer Europe expanded its membership and activities. The organization played a crucial role in putting dementia on the European policy agenda, contributing to the European Commission's first initiatives on mental health and cognitive decline. Key developments during this period included the establishment of the European Alzheimer's Alliance as an informal grouping of MEPs supportive of dementia research and care, and the creation of the first European dementia research coordination mechanisms.
The organization also began systematic data collection on dementia prevalence across Europe, producing landmark reports on the epidemiological landscape of dementia in European countries. This epidemiological work provided crucial evidence for policy advocacy and helped quantify the scale of the challenge facing European health systems.
The modern era has seen Alzheimer Europe transform into a sophisticated policy and research coordinator. The organization's strategic plans have increasingly emphasized research coordination, data sharing, and the involvement of people with dementia in research. The NEURONET project and other EU-funded initiatives represent the maturation of Alzheimer Europe into a genuine research coordinating body rather than simply an advocacy organization.
The Strategic Plan (2026-2030) represents the current framework guiding the organization's activities, building on decades of experience while addressing emerging challenges including demographic changes, new therapeutic developments, and the post-pandemic healthcare landscape.
Alzheimer Europe's current strategic plan articulates a comprehensive vision for transforming dementia care and research across Europe. The mission emphasizes the organization's commitment to making dementia a European priority, ensuring that the voices of people affected by dementia are central to all policy and research decisions. The strategic plan recognizes that Europe faces a growing dementia crisis as populations age, with prevalence expected to increase substantially in the coming decades.
The plan establishes five strategic priorities: strengthening the voice of people affected by dementia, coordinating European dementia research, influencing European policy, promoting good dementia care practices, and ensuring organizational sustainability. Each priority includes specific objectives and measurable outcomes that guide the organization's annual activities.
A central element of the strategic plan is strengthening Alzheimer's Europe's role in coordinating European dementia research. The organization aims to increase cross-border collaboration, promote data sharing among European research institutions, and ensure that research priorities reflect the needs and preferences of people living with dementia. The plan recognizes that European dementia research has been fragmented, with national efforts often duplicating each other rather than leveraging collective resources.
The research coordination strategy includes supporting the establishment of European research consortia, advocating for dedicated EU funding for dementia research, and developing infrastructure for shared data resources. Alzheimer Europe also aims to increase patient involvement in research design and implementation, ensuring that studies address outcomes that matter most to people living with dementia and their families.
The strategic plan outlines ambitious policy advocacy objectives at both European and national levels. At the European level, the organization works to influence EU health policy, secure funding for dementia research through framework programs, and promote dementia-friendly policies across member states. At the national level, Alzheimer Europe supports member organizations in their efforts to develop and implement national dementia strategies.
Key policy priorities include ensuring access to new disease-modifying treatments, promoting early diagnosis and intervention, improving care quality standards, and addressing the needs of underserved populations including people with young-onset dementia and those from ethnic minority backgrounds.
NEURONET (Networking for Efficient Transition from Academic Research to Ageing) is one of Alzheimer Europe's flagship research coordination initiatives. This EU-funded project brings together academic research institutions, pharmaceutical companies, and patient organizations to accelerate Alzheimer's disease drug development. The project addresses critical gaps in European Alzheimer's research by creating infrastructure for data sharing, harmonizing research methodologies, and facilitating collaboration across national boundaries.
The NEURONET consortium includes leading European research institutions and has established working groups focused on data sharing, biomarker standardization, and clinical trial optimization. The project has produced several landmark publications on best practices for European Alzheimer's research and has developed recommendations for improving the efficiency of clinical trials in the region.
Alzheimer Europe participates in JPco-fuND, the EU Joint Programme on Neurodegenerative Disease Research. This initiative brings together national funding agencies from European countries to coordinate research on Alzheimer's disease, Parkinson's disease, and related conditions. JPco-fuND has funded numerous transnational research projects and established mechanisms for sharing research resources and expertise across national boundaries.
The organization's involvement in JPco-fuND demonstrates its commitment to coordinating European research efforts rather than duplicating national programs. Through this participation, Alzheimer Europe ensures that the perspectives of patient organizations are integrated into research priority-setting and that funded projects address questions relevant to people affected by dementia.
Alzheimer Europe has become a leading advocate for data sharing in dementia research. The organization recognizes that the complexity of neurodegenerative diseases requires large datasets that no single institution can generate independently. Through initiatives like the Dementia Evidence Tool and partnerships with European research databases, the organization promotes practices that maximize the value of research data.
The organization's data sharing work includes developing ethical frameworks for sharing sensitive patient data, creating technical infrastructure for secure data exchange, and advocating for policies that support open science in dementia research. These efforts have contributed to a growing culture of data sharing among European dementia researchers.
Alzheimer Europe has achieved significant policy impact at the European level. The organization's advocacy has contributed to increased EU funding for dementia research, the development of national dementia strategies in multiple member states, and the establishment of dementia as a recognized priority in European health policy. The European Alzheimer's Alliance, which the organization coordinates, has been instrumental in building political support for dementia-related initiatives.
The organization's policy influence extends to specific legislative and regulatory matters. Alzheimer Europe has provided input to EU regulations on health technology assessment, medical devices, and pharmaceutical approvals. These contributions ensure that the perspectives of people affected by dementia are considered in decisions that affect their care and treatment.
Through its research coordination activities, Alzheimer Europe has contributed to advancing dementia research across Europe. The organization's work has facilitated international collaborations, standardized research methodologies, and promoted the sharing of data and resources. These contributions have increased the efficiency and impact of European dementia research.
The organization also plays a crucial role in translating research findings into practice. Through publications like the Dementia in Europe magazine and the Dementia Evidence Tool, the organization ensures that research evidence reaches policymakers, healthcare professionals, and patient organizations. This translation function helps ensure that scientific advances benefit people affected by dementia.
Alzheimer Europe has contributed substantially to raising awareness about dementia across Europe. The organization's campaigns have challenged common misconceptions about dementia and promoted understanding that people living with dementia can live well with appropriate support. This awareness work has contributed to changing public attitudes and reducing stigma associated with dementia.
The organization's public education efforts include information resources available in multiple languages, public awareness campaigns, and engagement with media to promote accurate and respectful coverage of dementia. These activities complement the organization's policy and research work by creating a more supportive environment for people affected by dementia.
Alzheimer Europe maintains financial sustainability through a diversified funding portfolio. The organization receives core funding from the EU Health Programme, which supports coordination activities and policy work. Project-specific funding from EU research programs supports research coordination initiatives. Member organization contributions provide additional revenue, with contribution levels adjusted according to national income levels.
The organization also generates income through conference registrations, publication sales, and fees for specific services. This diversified funding model provides stability while allowing the organization to maintain independence in its advocacy and policy positions.
Alzheimer Europe maintains strong governance through its board structure, which includes representatives from member organizations across Europe. The board provides strategic direction and oversight, while the executive team manages day-to-day operations. The organization maintains transparency through publication of annual reports, financial statements, and detailed accounts of activities.
The organization is registered in the EU Transparency Register, providing public access to information about its funding and lobbying activities. This transparency commitment demonstrates the organization's accountability to its members and to the broader European public.
Alzheimer Europe faces several emerging challenges in its mission to improve lives of people affected by dementia across Europe. The demographic challenge of aging populations means that dementia prevalence will increase substantially in coming decades, creating growing demand for services and support. Healthcare systems across Europe face resource constraints that limit their capacity to meet this growing demand.
The rapidly evolving therapeutic landscape presents both opportunities and challenges. New disease-modifying treatments for Alzheimer's disease are becoming available, but healthcare systems are struggling to implement the diagnostic infrastructure needed to identify eligible patients. Alzheimer Europe must advocate for investment in diagnostic capacity while ensuring that new treatments are accessible to all who could benefit.
Despite challenges, Alzheimer Europe also sees significant opportunities for advancing its mission. The growing recognition of dementia as a policy priority creates opportunities for influencing policy at both European and national levels. Advances in research, including new biomarkers and therapeutic approaches, offer hope for improved outcomes that the organization can help translate into practice.
The organization's position as the voice of European dementia associations provides unique opportunities to coordinate action across national boundaries. By leveraging its network of member organizations, Alzheimer Europe can amplify the impact of national efforts and create European-level change that individual countries could not achieve alone.
Alzheimer Europe represents a vital coordinating body for dementia research, policy, and advocacy across Europe. Through its work coordinating research, influencing policy, and representing the voices of people affected by dementia, the organization contributes to improving the lives of millions of Europeans living with dementia and their families. As the organization implements its Strategic Plan (2026-2030), it remains committed to its mission of making dementia a European priority and ensuring that the perspectives of people affected by dementia are central to all efforts to address this challenging condition.
The following diagram shows key molecular relationships for alzheimer-europe based on knowledge graph edges:
Related Hypotheses:
The following diagram shows the key molecular relationships involving alzheimer-europe discovered through SciDEX knowledge graph analysis: